Atai Life Sciences acquires exclusive rights to Psilera’s DMT patent portfolio
Atai Life Sciences has taken a strategic step in expanding its position in psychedelic medicine by securing exclusive rights to Psilera Inc.’s DMT patent portfolio. ... Read More
Avid Bioservices to exit public market with GHO and Ampersand buyout
In a transformative shift within the biopharmaceutical manufacturing sector, Avid Bioservices, a premier biologics contract development and manufacturing organization (CDMO), has announced its agreement to ... Read More
Ascentage Pharma receives $100m payment from Takeda under exclusive option agreement
Ascentage Pharma, a leading global biopharmaceutical company specializing in novel therapies for cancer and other serious diseases, has announced the receipt of a US$100 million ... Read More
Ovid Therapeutics announces significant workforce reduction to extend cash runway
Ovid Therapeutics Inc., a New York-based biopharmaceutical company, has announced a significant reduction in its workforce. This decision, approved by the Board of Directors on ... Read More
Cycle Pharmaceuticals proposes $466m acquisition of Vanda Pharmaceuticals
In a significant development within the pharmaceutical industry, UK-based Cycle Pharmaceuticals has offered to acquire Nasdaq-listed Vanda Pharmaceuticals in an all-cash transaction valued at $466 ... Read More
Roche to strengthen gene therapy portfolio with Spark Therapeutics acquisition
Swiss pharmaceutical giant Roche has reached a major agreement to acquire the U.S.-based gene therapy company Spark Therapeutics in an all-cash deal valued at $4.3 ... Read More
PTC Therapeutics completes $200m acquisition of Agilis Biotherapeutics to expand gene therapy portfolio
In a major strategic move, US biopharmaceutical company PTC Therapeutics has finalized its acquisition of Agilis Biotherapeutics, a biotech firm specializing in the development of ... Read More